肿瘤细胞治疗研究
英文原题：FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.
FAP-CD40 与 PD1-IL2v 的联合为治疗浸润不良的冷肿瘤提供了一种有前景的策略。
背景：胰腺导管腺癌（PDAC）免疫学上属于“冷”肿瘤，T细胞浸润差且肿瘤微环境高度抑制，因此免疫治疗仍面临重大挑战。我们提出一种新策略：联合使用FAP-CD40在肿瘤微环境中激活树突状细胞（DC），并使用PD-1-白细胞介素2变体（IL-2v）促进肿瘤浸润T细胞扩增和分化。我们假设，该联合方案可在胰腺4662 KPC肿瘤内直接协同增强T细胞启动和扩增；该模型可重现人PDAC的免疫“冷”特征。 方法：采用多重共聚焦成像（三维免疫表型分析），研究FAP-CD40/PD-1-IL-2v单药或联合治疗后的免疫细胞分布和丰度。FTY720实验评估淋巴结启动对治疗效果的贡献；耗竭CD4+/CD8+ T细胞的实验用于确定这些亚群在联合治疗中的作用。通过离体再刺激实验和单细胞RNA测序进一步评估T细胞功能。 结果：联合治疗诱导形成致密的肿瘤内CD4+和CD8+ T细胞簇，并与1型常规DC共定位，称为T细胞-DC簇（TDC）。TDC与肿瘤消退高度相关，且该消退需要CD4+和CD8+ T细胞共同参与。与单药治疗组相比，联合治疗组肿瘤来源T细胞功能增强，肿瘤坏死因子α和干扰素γ产生增加。单细胞RNA测序显示，联合治疗组肿瘤内CD4+ T细胞向辅助性T细胞1型表型极化。 结论：FAP-CD40与PD-1-IL-2v联合治疗为浸润不足的“冷”肿瘤提供了有前景的策略。通过驱动T细胞浸润、促进新生TDC形成并协调局部抗肿瘤免疫，该策略为未来靶向免疫治疗耐药肿瘤提供了基础。
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for immunotherapy due to its immunologically cold tumor nature, characterized by poor T cell infiltration and a highly suppressive tumor microenvironment. Here, we propose a novel strategy, combining fibroblast activation protein (FAP)-CD40 to activate dendritic cells (DCs) in the tumor microenvironment and programmed cell death protein-1 (PD1)-interleukin 2v (IL2v) to promote the expansion and differentiation of tumor-infiltrating T cells. We hypothesize that this combination will synergistically enhance both T cell priming and expansion directly within pancreatic 4662 KPC tumors, which recapitulate the immunologically cold features of human PDAC. METHODS: Immune cell distribution and abundance following FAP-CD40/PD1-IL2v monotherapy or combination therapy were analyzed using multiplexed confocal imaging (3D immune phenotyping). FTY720 studies assessed the contribution of lymph node priming in treatment efficacy, while CD4+/CD8+ T cell depletion experiments identified the roles of these subsets in combination therapy. T cell functionality was further assessed through ex vivo restimulation assays and single-cell RNA sequencing. RESULTS: Combination therapy induced dense intratumoral clusters of CD4 + and CD8 + T cells, colocalized with type 1 conventional DCs, termed as T cell-DC clusters (TDCs). These TDCs were strongly associated with tumor regression, which required both CD4 + and CD8 + T cells. Furthermore, T cells from combination-treated tumors showed enhanced functionality, with increased tumor necrosis factor-alpha and interferon-gamma production compared with monotherapy groups. Single-cell RNA sequencing revealed polarization of CD4 + T cells toward a T helper cell 1 phenotype in combination-treated tumors. CONCLUSION: The combination of FAP-CD40 and PD1-IL2v offers a promising strategy for treating poorly infiltrated, cold tumors. By driving T cell infiltration, promoting de novo TDC formation and orchestrating local antitumor immunity, this strategy provides a foundation for future therapies targeting immunotherapy-resistant tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
